Literature DB >> 10621835

Proteolysis in colorectal cancer.

E A Garbett1, M W Reed, N J Brown.   

Abstract

BACKGROUND: The process of metastasis is complex, involving many interrelated stages, including proteolysis. Proteolysis occurs in both normal and pathological processes and involves the breakdown of the extracellular matrix and/or basement membrane by proteolytic enzymes. Normally, proteolysis is tightly controlled by specific endogenous proteinase inhibitors. However, in certain disease processes, including cancer, controlled but abnormal proteolysis seems to occur. Proteinases involved in tumour invasion and metastasis include the matrix metalloproteinases (MMPs) and the serine proteinases. AIMS: To gain a greater understanding of the proteolytic process occurring in colorectal cancer and to determine which, if any, proteinases are upregulated.
METHODS: The synthesis of proteinases and their inhibitors was compared in paired tumour and normal tissue samples from patients with colorectal cancer (n = 24). Substrate zymography was used to determine the synthesis of MMPs (MMP-2, MMP-9, and MMP-3) and the plasminogen activators (urokinase and tissue-type plasminogen activators); enzyme linked immunosorbent assays (ELISAs) were used to determine the concentrations of MMP-1 and tissue inhibitor of metalloproteinase 1 (TIMP-1); and the technique of quenched fluorescence substrate hydrolysis was performed to determine the total MMP activity of each sample.
RESULTS: In general, both proteinase and inhibitor expression was greater in the tumour tissue when compared with the corresponding normal colorectal tissue. The amount of active MMPs was greater in the tumour tissue.
CONCLUSIONS: The increased extracellular proteinase concentrations and activity may encourage tumour invasion and metastasis. This study points to MMP-9 as being of potential major importance in the development of this form of cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621835      PMCID: PMC395688          DOI: 10.1136/mp.52.3.140

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  29 in total

Review 1.  Matrix-degrading metalloproteinases in tumor progression.

Authors:  L M Matrisian; J Wright; K Newell; J P Witty
Journal:  Princess Takamatsu Symp       Date:  1994

2.  Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9.

Authors:  Z S Zeng; Y Huang; A M Cohen; J G Guillem
Journal:  J Clin Oncol       Date:  1996-12       Impact factor: 44.544

3.  Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.

Authors:  L Buø; G I Meling; T S Karlsrud; H T Johansen; A O Aasen
Journal:  Hum Pathol       Date:  1995-10       Impact factor: 3.466

4.  A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases.

Authors:  C G Knight; F Willenbrock; G Murphy
Journal:  FEBS Lett       Date:  1992-01-27       Impact factor: 4.124

5.  Electrophoretic analysis of proteins associated with tumor cell invasion.

Authors:  R E Seftor
Journal:  Electrophoresis       Date:  1994 Mar-Apr       Impact factor: 3.535

6.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

7.  Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers.

Authors:  M Yoshimoto; F Itoh; H Yamamoto; Y Hinoda; K Imai; A Yachi
Journal:  Int J Cancer       Date:  1993-06-19       Impact factor: 7.396

8.  Tissue-type plasminogen activator, a new prognostic marker in breast cancer.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H R Lijnen
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

9.  Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage.

Authors:  P Ring; K Johansson; M Höyhtyä; K Rubin; G Lindmark
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.

Authors:  Z S Zeng; J G Guillem
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more
  7 in total

1.  Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Authors:  Judith Y M N Engwegen; Helgi H Helgason; Annemieke Cats; Nathan Harris; Johannes M G Bonfrer; Jan H M Schellens; Jos H Beijnen
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

2.  Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus.

Authors:  Aron Altorjay; Balazs Paal; Nicolette Sohar; Janos Kiss; Imre Szanto; Istvan Sohar
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

3.  Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells.

Authors:  Dan Shen; Changsheng Deng; Ming Zhang
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

4.  Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium.

Authors:  Deborah L Ornstein; Kenneth H Cohn
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

Review 5.  Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.

Authors:  Xiao-Feng Sun; Hong Zhang
Journal:  Mol Cancer       Date:  2006-10-06       Impact factor: 27.401

6.  Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness.

Authors:  L-B Weiswald; S Richon; P Validire; M Briffod; R Lai-Kuen; F P Cordelières; F Bertrand; D Dargere; G Massonnet; E Marangoni; B Gayet; M Pocard; I Bieche; M-F Poupon; D Bellet; V Dangles-Marie
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

7.  Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer.

Authors:  E T Waas; R M L M Lomme; J DeGroot; Th Wobbes; T Hendriks
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.